|Awarded On||February 19, 2014|
|Title||Novel Ceramide-modulating Therapeutics for Cancer Use|
|Program||Product Development Research|
|Award Mechanism||Company Formation|
|Principal Investigator/Program Director||Richard Love|
CerRx is developing drugs to trick cancer cells into overproducing toxic waxes, called ceramides. When the ceramides increase to a certain level, cancer cells die. CerRx has a pipeline of such drugs, including fenretinide and safingol, which work synergistically against many cancer types in laboratory testing. Human testing already shows fenretinide eliminates the cancers of some patients with relapsed lymphomas.
CerRx needs funding to advance these drugs to market, specifically for the following clinical trials to be conducted in Texas-based consortia: 1) a larger trial of fenretinide in advanced Peripheral T-cell lymphoma, 2) a larger trial in advanced Cutaneous T-cell lymphoma, and 3) a t...